Meet Novartis AG Management Investor Event - Breakout Sessions (Day 2) Transcript
Very good. I think we can get started. So welcome everybody to the oncology session. Let me first introduce the team here. My name is Susanne Schaffert. I am the CEO of Oncology appointed since January. And I have a great team with me. On the very far out here is our Head of Research for Oncology based here in NIBR, Jeff Engelman. Then we have our Head of the U.S. Operations, Ameet Mallik, here with us. We have our CFO, Teresa Jose, with us. And we have our Head of the Cell and Gene Therapies namely Kymriah and other promising stuff, Pascal Touchon, here.
So maybe let me give you a short introduction before we go into Q&A. We feel quite good about oncology these days. Maybe you have seen our Q1 results, very strong performance, 9% growth. And that is really based on a quite robust portfolio. We have 7 blockbusters in the portfolio, 3 of these blockbusters growing high double digit. And that are namely Mekinist + Tafinlar, there is Jakavi and there is Promacta/Revolade. We have also 3 products that are very promising and have the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
